Log In
Print
BCIQ
Print
Print this Print this
 

AGS-004

  Manage Alerts
Collapse Summary General Information
Company Argos Therapeutics Inc.
DescriptionAutologous dendritic cell immunotherapy transfected with the patient's viral RNA antigens
Molecular Target Not applicable
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationHIV / AIDS
Indication DetailsTreat chronic HIV-1 infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$40.1M

0

$30.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today